{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:07:23Z","timestamp":1790140043788,"version":"4.0.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculous meningitis (TBM) remains the most severe form of tuberculosis. Linezolid- and fluoroquinolone-containing regimens are used in clinical practice, but their associations with mortality and specific toxicities in non-HIV TBM remain uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center retrospective cohort study of non-HIV patients with TBM hospitalized between October 2013 and January 2024. The exposures were recorded linezolid use, fluoroquinolone-class use, and combined linezolid-fluoroquinolone use during the index hospitalization. Each indexed exposure was compared with no recorded use of that exposure; for the combined analysis, the comparator was not-both exposure (either agent alone or neither agent). Outcomes were in-hospital all-cause death and drug-induced liver injury (DILI) documented during the index hospitalization. Propensity score-based inverse probability of treatment weighting and doubly robust weighted logistic regression with model-robust sandwich standard errors were used. Propensity score matching, complete-case analysis, 20-dataset multiple imputation, a sensitivity analysis restricted to age, sex, diabetes mellitus, and immunodeficiency, and subgroup interaction analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1,574 patients, 187 died in hospital and 116 had DILI documented during the index hospitalization. Linezolid was recorded in 996 patients, fluoroquinolone-class therapy in 859, and both in 556. After weighting, all modeled covariates had absolute standardized mean differences below 0.10. None of the three recorded exposures was significantly associated with in-hospital death or DILI documented during the index hospitalization. Complete-case, multiple-imputation, and temporally restricted sensitivity estimates were directionally consistent with the primary results. None of the prespecified exposure-by-subgroup interactions was statistically significant after outcome-specific multiplicity adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Recorded in-hospital linezolid, fluoroquinolone, and combined exposure were not significantly associated with in-hospital death or DILI documented during the index hospitalization in this cohort. The estimates apply to recorded inpatient exposure and DILI and do not establish the effects of treatment initiation at a defined time or the overall safety of these regimens. For DILI, the data do not establish that the liver event occurred after linezolid or fluoroquinolone initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1907126","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:44:17Z","timestamp":1790138657000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations of recorded in-hospital linezolid and fluoroquinolone exposure with mortality and documented drug-induced liver injury in non-HIV tuberculous meningitis: a propensity score-weighted real-world cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Wengao","family":"Zeng","sequence":"first","affiliation":[{"name":"Department of Neurology, The Second Hospital of Changsha (West Branch of Changsha Hospital for Maternal & Child Health Care)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Hospital of Changsha (West Branch of Changsha Hospital for Maternal & Child Health Care)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Second Hospital of Changsha (West Branch of Changsha Hospital for Maternal & Child Health Care)","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jue","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1016\/S1473-3099(25)00364-0","article-title":"A clinical practice guideline for tuberculous meningitis","volume":"26","author":"Donovan","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1474-4422(21)00435-X","article-title":"Tuberculous meningitis: progress and remaining questions","volume":"21","author":"Huynh","year":"2022","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1080\/14787210.2025.2579210","article-title":"Updates in the clinical management of tuberculous meningitis","volume":"24","author":"Garg","year":"2026","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/cid\/ciab992","article-title":"Cycloserine and linezolid for tuberculosis meningitis: pharmacokinetic evidence of potential usefulness","volume":"75","author":"Kempker","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1093\/infdis\/jiad413","article-title":"Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis","volume":"229","author":"Abdelgawad","year":"2024","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"ofaf503","DOI":"10.1093\/ofid\/ofaf503","article-title":"Intensified treatment of tuberculous meningitis in adults: a systematic review and meta-analysis","volume":"12","author":"Llamas-Lopez","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk","year":"2016","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1093\/cid\/ciac932","article-title":"A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus-associated tuberculous meningitis: the LASER-TBM trial","volume":"76","author":"Davis","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/cid\/cix230","article-title":"Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen","volume":"65","author":"Heemskerk","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"key":"B13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12072-021-10144-3","article-title":"Drug-induced liver injury: Asia Pacific association of study of liver consensus guidelines","volume":"15","author":"Devarbhavi","year":"2021","journal-title":"Hepatol Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1111\/liv.14896","article-title":"Incidence and risk factors of anti-tuberculosis drug-induced liver injury: a large cohort study involving 4652 Chinese adult tuberculosis patients","volume":"41","author":"Jiang","year":"2021","journal-title":"Liver Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1406454","DOI":"10.3389\/fphar.2024.1406454","article-title":"Clinical risk factors for moderate and severe antituberculosis drug-induced liver injury","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(10)70138-9","article-title":"Tuberculous meningitis: a uniform case definition for use in clinical research","volume":"10","author":"Marais","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: multivariate imputation by chained equations in R","volume":"45","author":"Van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v009.i08","article-title":"Analysis of complex survey samples","volume":"9","author":"Lumley","year":"2004","journal-title":"J Stat Softw"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1048653","DOI":"10.3389\/fphar.2022.1048653","article-title":"Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis","volume":"13","author":"Maranchick","year":"2022","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kwq439","article-title":"Doubly robust estimation of causal effects","volume":"173","author":"Funk","year":"2011","journal-title":"Am J Epidemiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/aje\/kwy210","article-title":"Propensity score-based estimators with multiple error-prone covariates","volume":"188","author":"Hong","year":"2019","journal-title":"Am J Epidemiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jtho.2020.12.008","article-title":"Statistical considerations for subgroup analyses","volume":"16","author":"Wang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","article-title":"Treating individuals 2: subgroup analysis in randomised controlled trials: importance, indications, and interpretation","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1907126\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:44:30Z","timestamp":1790138670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1907126\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":30,"alternative-id":["10.3389\/fmed.2026.1907126"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1907126","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1907126"}}